NKTR supply chain intelligence for Nektar Therapeutics: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Nektar Therapeutics (NKTR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TAK | Takeda Pharmaceutical Company Limited | 95% | Reciprocal relationship from TAK graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from TAK graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from TAK grap… |
| FLG | Flagstar Bank, National Association | 92% | Reciprocal relationship from FLG graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from FLG graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from FLG grap… |
| GANNET-BIOCHEM | GANNET-BIOCHEM | 92% | we are dependent on Gannet BioChem for the supply of PEG reagents |
| JEFFERIES-LLC | JEFFERIES-LLC | 92% | On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (coll… |
| PIPER-SANDLER-CO | PIPER-SANDLER-CO | 92% | On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (coll… |
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 92% | On April 21, 2026, Nektar Therapeutics (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. (coll… |
| FLG | Flagstar Bank, National Association | 90% | In connection with Ms. Rubinstein's becoming the Company's interim Chief Financial Officer, the Company entered into an amendment (the "Amendment") to its consulting agreement with FLG for the provis… |
| ASND | Ascendis Pharma A/S | 72% | Reciprocal relationship from ASND graph: roduct containers and closures; production and process controls; packaging and labeling controls; holding and distribution; laboratory controls; records and r… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced sol… |
| HCWB | HCW Biologics Inc. | 72% | Reciprocal relationship from HCWB graph: and HCW9302). The production campaigns include sufficient quantities of clinical grade materials required to complete the Phase 1 or Phase 2 clinical trials w… |
| IMA | ImageneBio, Inc. | 72% | Reciprocal relationship from IMA graph: ntures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and com… |
| IOBTQ | IOBTQ | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| IOBTQ | IOBTQ | 72% | Reciprocal relationship from IOBTQ graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual p… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual pro… |
| LLY | Eli Lilly and Company | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from NKTR graph: . We currently do not intend to sell these securities prior to maturity and it is more likely than not that we will no… |
| NVO | Novo Nordisk A/S | 72% | . We currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis… |
| ODTX | ODTX | 72% | to target the TNFR2 pathway and include Dualyx, TRexBio, Inc., Odyssey Therapeutics, Inc., and Pfizer, Inc. Research and Development Our total research and development expenditures can be disaggregat… |
| ODTX | ODTX | 72% | Reciprocal relationship from ODTX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from ODTX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from ODTX g… |
| PRRUF | PRRUF | 72% | Reciprocal relationship from PRRUF graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PRRUF graph: . 28 Table of Contents IMP761 Preclinical Development On January 3, 2017 w… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual pr… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from NKTR graph: em 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses rela… |
| SNYNF | Sanofi | 72% | em 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, i… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from TKPH… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| UCB | United Community Banks, Inc. | 85% | Reciprocal relationship from UCB graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from UCB graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from UCB grap… |
| BHC | Bausch Health Companies Inc. | 72% | Reciprocal relationship from BHC graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from BHC graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from BHC grap… |
| BHC | Bausch Health Companies Inc. | 72% | the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the study… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from NKTR graph: tal common stock reserved for issuance 3,300,607 4,571,228 Note 9 — License and Collaboration Agreements We have enter… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from BMYM… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: source for their respective manufacturing and supplies. Failure of any of these contractors could affect our ability to have clinical trial material available… |
| HCWB | HCW Biologics Inc. | 72% | Reciprocal relationship from HCWB graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from HCWB graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from HCWB g… |
| IOBTQ | IOBTQ | 72% | Reciprocal relationship from IOBTQ graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual p… |
| IOBTQ | IOBTQ | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual pro… |
| LLY | Eli Lilly and Company | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| NVO | Novo Nordisk A/S | 72% | . We currently do not intend to sell these securities prior to maturity and it is more likely than not that we will not be required to sell these securities before we recover the amortized cost basis… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from NVO graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from NVO grap… |
| ODTX | ODTX | 72% | Reciprocal relationship from ODTX graph: Reciprocal relationship from NKTR graph: n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual pr… |
| ODTX | ODTX | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| PLRX | Pliant Therapeutics, Inc. | 72% | Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PLRX g… |
| PRRUF | PRRUF | 72% | Reciprocal relationship from PRRUF graph: . 28 Table of Contents IMP761 Preclinical Development On January 3, 2017 we announced a new early stage product candidate to be known as IMP761, developed in… |
| PSTV | Plus Therapeutics, Inc. | 72% | Reciprocal relationship from PSTV graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PSTV graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from PSTV g… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from SGMO g… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | n. Please refer to Item 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commerciall… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from SNYN… |
| SNYNF | Sanofi | 72% | em 1A. Risk Factors, including without limitation, “We may not be able to obtain intellectual property licenses related to the development of our drug candidates on a commercially reasonable basis, i… |
| TAK | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TAK graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from TAK graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from TAK grap… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from TKPH… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the study… |
| ASTRAZENECA-AB-BAXALTA-INC | ASTRAZENECA-AB-BAXALTA-INC | 62% | or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the st… |
| AZN | AstraZeneca PLC | 62% | Reciprocal relationship from AZN graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from AZN graph: Reciprocal relationship from NKTR graph: or the 18 µg/kg rezpegaldesleukin arm… |
| BIOLOJIC-DESIGN-LTD | BIOLOJIC-DESIGN-LTD | 62% | or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the st… |
| F-HOFFMANN-LA-ROCHE-LTD | F-HOFFMANN-LA-ROCHE-LTD | 62% | or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the st… |
| HEALTHCARE-ROYALTY-MANAGEMENT-LLC | HEALTHCARE-ROYALTY-MANAGEMENT-LLC | 62% | or the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.121, respectively) was observed. At all timepoints, the rezpegaldesleukin treatment arms separated from placebo in the st… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NKTR-DEBT | Debt stack $133.5M | 90% | Market cache reports total debt of $133.5M. |
| NKTR-DEBT-11282 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2011-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| NKTR-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 209 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| AKTS | Aktis Oncology, Inc. | 100.00 | 2 | |
| FHTX | Foghorn Therapeutics Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| AMGN | Amgen Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| CANF | Can-Fite BioPharma Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | ['customer'] |